Quality tools can last you a lifetime… Even a basic set may be enough for you to do the job well, day in and day out. But you'll have limitations… A master craftsman can tell you that certain jobs require specialized tools. Having these tools at the right times – and knowing how to use them – can prove extremely valuable. Trading is no different… If you're a trader, you should have all the basics in your "toolbox"… the tools that allow you to plan and execute your trades well every time. These are things like position sizing, stop losses, and a variety of trading techniques (including buying stocks, trading for income, and short selling). You can make a lot of money in the market by using these basic tools well. But one of my goals is to show you how to use a variety of specialized tools, too…
Top High Tech Stocks To Invest In 2017: Rennova Health, Inc.(RNVA)
- [By Ashley Moore]
Here is a list of the top 10 best small-cap stocks based on price gains per share so far in 2017:
Company (Ticker)Price per Share% Change AquaBounty Technologies Inc. (Nasdaq: AQB)$14.338,646.99%Rennova Health Inc. (Nasdaq: RNVA)$3.133,333.73%China Gengsheng Minerals Inc. (OTCMKTS: CHGS)$0.021,718.18%Sunshine Heart Inc. (Nasdaq: SSH)$3.851,071.43%CTI BioPharma Corp. (Nasdaq: CTIC)$4.30991.76%Catalyst Biosciences Inc. (Nasdaq: CBIO)$6.22853.85%TearLab Corp. (Nasdaq: TEAR)$4.20707.85%Pulmatrix Inc. (Nasdaq: PULM)$3.86566.10%Real Goods Solar Inc. (Nasdaq: RGSE)$1.43498.75%Calithera Biosciences Inc. (Nasdaq: CALA)$11.70281.54%
Top High Tech Stocks To Invest In 2017: Tree.com Inc.(TREE)
- [By Douglas A. McIntyre]
Many of the sponsors of Bill O’Reilly’s Fox show, “The O’Reilly Factor,” have cancelled ads in the wake of a sexual harassment scandal. However, two mainstream advertisers continue to support O’Reilly online via ads on his Bill O’Reilly website. Based on observations over the past 24 hours, these include LendingTree Inc. (NASDAQ: TREE) and the Hefty division of Reynolds Consumer Products.
- [By WWW.THESTREET.COM]
Coming up on this episode of Mad Money: Cramer interviews United Technologies (UTX) CEO Greg Hayes; and Doug Lebda, CEO of LendingTree (TREE) . Plus, don’t miss the Lightning Round. Which stocks is Cramer bullish on?
Top High Tech Stocks To Invest In 2017: VistaGen Therapeutics, Inc. (VTGN)
- [By SEEKINGALPHA.COM]
Four ideas turned up in this screen that might be of interest (prices as of February 9th close):
Heron Therapeutics (NASDAQ:HRTX) by ONeil Trader – published February 3rd, 2017, $525M Market cap, down ~2% since publication, author’s price target offers 130% upside. HRTX isn’t a generic drug provider, but its CINV franchise vs. the growth of a new drug gives it a similar sort of profile, and arguably a favorable risk/reward; commenters were mostly positive on the thesis. VistaGen Therapeutics (OTC:VTGN) by Logical Assessment – published July 29, 2016, $24M market cap, down 16% since publication, author’s price target offers 100%+ upside. This is obviously deeper into the speculative pile, but if the author’s thesis holds about VistaGen’s unique angle in the antidepressant drug space, comparable deals suggest good upside. (Of course, it’s always dangerous to rely solely on comparables). Dr. Reddy’s Laboratories (NYSE:RDY) by Buddy Lyons – published July 5, 2016, $7.6B m arket cap, down ~13% since publication, author’s price target offers just shy of 100% upside. Dr. Reddy’s is a more obvious comparable to TEVA, with a generics business but also a manufacturing business and a proprietary products branch. The company bought a divestiture package of drugs from TEVA as part of the Allergan/Actavis deal. A big overhang was an FDA warning letter; the FDA is due to reinspect facilities this month or next, which could resolve that one way or another. Lannett (NYSEMKT:LCI) by Lateral Capital Management – published May 27, 2016, $750M market cap, down ~9% since publication, author’s price target offers 75% upside. LCI’s trading had been 90% correlated with Valeant, but Lateral Capital Management argues that the correlation is unjustified. The article does a deep dive into the company’s valuation and credit risk, and was well received at the time, even if the market hasn’t agreed…yet.
I also checked to see if there are any ideas starting to play out on the short si